JNJ Stock Surges on Product Swap
Johnson & Johnson's (JNJ) stock surged by 54% between late August 2025 and late August 2026, outperforming the S&P 500's 20.5% return over the same period.
The company's financials didn't signal this growth, but a product swap did. In its fourth-quarter 2024 report, JNJ management disclosed that it was positioning next-generation immunology assets to offset biosimilar erosion.
One of these launches was TREMFYA in inflammatory bowel disease (IBD), which was named even though it was growing at only 5.6% at the time. Six months later, in July 2025, STELARA had fallen by 43.2%, while TREMFYA had risen by 30.1%. This growth was significant because about 70% of STELARA's prescriptions were for IBD.
In July 2026, JNJ announced several key developments: the FDA authorized its OTTAVA surgical robot, the company proposed a comprehensive resolution for remaining ovarian talc litigation, and the Firefly Bio acquisition closed. However, it was the commercial swap that provided the structural floor under the financials.